Artículos por temáticas

Network activity changes in the pathophysiology of Alzheimer's disease: the role of aging and early entorhinal cortex dysfunction

Setti SE, Reed MN.

Metab Brain Dis. 2022 Feb;37(2):289-298. doi: 10.1007/s11011-021-00848-8. Epub 2021 Sep 30.

Traumatic Brain Injury and Risk of Dementia and Alzheimer's Disease: A Systematic Review and Meta-Analysis

Gu D, Ou S, Liu G.

Neuroepidemiology. 2022;56(1):4-16. doi: 10.1159/000520966. Epub 2021 Nov 24.

Vascular Cognitive Impairment (VCI)

Rundek T, Tolea M, Ariko T, Fagerli EA, Camargo CJ.

Neurotherapeutics. 2022 Jan;19(1):68-88. doi: 10.1007/s13311-021-01170-y. Epub 2021 Dec 22.

A Case of Possible Chronic Traumatic Encephalopathy and Alzheimer's Disease in an Ex-Football Player

Fesharaki-Zadeh A.

Neurologist. 2022 Sep 1;27(5):249-252. doi: 10.1097/NRL.0000000000000391.

Observational study of patient characteristics associated with a timely diagnosis of dementia and mild cognitive impairment without dementia

White L, Ingraham B, Larson E, Fishman P, Park S, Coe NB.

J Gen Intern Med. 2022 Sep;37(12):2957-2965. doi: 10.1007/s11606-021-07169-7. Epub 2021 Oct 13.

The role of Alzheimer's disease risk genes in endolysosomal pathways

Szabo MP, Mishra S, Knupp A, Young JE.

Neurobiol Dis. 2022 Jan;162:105576. doi: 10.1016/j.nbd.2021.105576. Epub 2021 Dec 3.

Astrocyte Reactivity in Alzheimer's Disease: Therapeutic Opportunities to Promote Repair

Mirzaei N, Davis N, Chau TW, Sastre M.

Curr Alzheimer Res. 2022;19(1):1-15. doi: 10.2174/1567205018666211029164106.

A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment

Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT, Wingo TS, Hales CM, Gámez Tansey M, Goldstein DS, Abrol A, Calhoun VD, Goldstein FC, Hajjar I, Fagan AM, Galasko D, Ed

Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452.

The Swedish dilemma - the almost exclusive use of APPswe-based mouse models impedes adequate evaluation of alternative β-secretases

Armbrust F, Bickenbach K, Marengo L, Pietrzik C, Becker-Pauly C.

Biochim Biophys Acta Mol Cell Res. 2022 Mar;1869(3):119164. doi: 10.1016/j.bbamcr.2021.119164. Epub 2021 Oct 23.

Neuroimaging alterations in dementia with Lewy bodies and neuroimaging differences between dementia with Lewy bodies and Alzheimer's disease: An activation likelihood estimation meta-analysis

Ma WY, Tian MJ, Yao Q, Li Q, Tang FY, Xiao CY, Shi JP, Chen J.

CNS Neurosci Ther. 2022 Feb;28(2):183-205. doi: 10.1111/cns.13775. Epub 2021 Dec 6.

A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer's Disease

Kumar M, Bansal N.

Curr Drug Targets. 2022;23(5):486-512. doi: 10.2174/1389450122666211118125233.

Dissecting the complexities of Alzheimer disease with in vitro models of the human brain

Blanchard JW, Victor MB, Tsai LH.

Nat Rev Neurol. 2022 Jan;18(1):25-39. doi: 10.1038/s41582-021-00578-6. Epub 2021 Nov 8.

Age dependence of retinal vascular plexus attenuation in the triple transgenic mouse model of Alzheimer's disease

Nazari HK, Karimaghaei C, van der Merwe R, Montalbano M, Taglialatela G, Vargas G, Zhang W, Motamedi M.

Exp Eye Res. 2022 Jan;214:108879. doi: 10.1016/j.exer.2021.108879. Epub 2021 Dec 10.

Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease

Brod SA.

J Alzheimers Dis. 2022;85(2):457-472. doi: 10.3233/JAD-215125.

Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research

Matuszyk MM, Garwood CJ, Ferraiuolo L, Simpson JE, Staniforth RA, Wharton SB.

J Neurochem. 2022 Feb;160(4):434-453. doi: 10.1111/jnc.15538. Epub 2021 Nov 24.